Kushenin Combined with Nucleostide Analogues for Chronic Hepatitis B: A Systematic Review and Meta-AnalysisReportar como inadecuado




Kushenin Combined with Nucleostide Analogues for Chronic Hepatitis B: A Systematic Review and Meta-Analysis - Descarga este documento en PDF. Documentación en PDF para descargar gratis. Disponible también para leer online.

Evidence-Based Complementary and Alternative Medicine - Volume 2015 2015, Article ID 529636, 12 pages -

Review Article

China Military Institute of Chinese Medicine, 302 Hospital of People’s Liberation Army, Beijing 100039, China

Pharmacy College, Chengdu University of Traditional Chinese Medicine, Chengdu 611137, China

Department of Integrative Medical Center, 302 Hospital of People’s Liberation Army, Beijing 100039, China

Received 19 March 2015; Revised 23 June 2015; Accepted 2 July 2015

Academic Editor: Hyunsu Bae

Copyright © 2015 Zhe Chen et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

Objective. To evaluate the efficacy and safety of Kushenin KS combined with nucleoside analogues NAs for chronic hepatitis B CHB. Methods. Randomized controlled trials RCTs of KS combined with NAs for CHB were identified through 7 databases. Frequencies of loss of serum HBeAg, HBeAg seroconversion, undetectable serum HBV-DNA, ALT normalization, and adverse events at 48 weeks were abstracted by two reviewers. The Cochrane software was performed to assess the risk of bias in the included trials. Data were analyzed with Review Manager 5.3 software. Results. 18 RCTs involving 1684 subjects with CHB were included in the analysis. KS combined with NAs including lamivudine LAM, entecavir ETV, adefovir dipivoxil ADV, and telbivudine TLV showed different degree of improvement in CHB indices. KS combined with NAs increased the frequency of loss of serum HBeAg, HBeAg seroconversion, undetectable HBV-DNA levels, and ALT normalization compared with single agents. It also decreased serum ALT and AST level after one-year treatment. However, KS combined with TLV did not show a significant difference in CHB indices. The side-effects of KS combined with NAs were light and of low frequency. Conclusion. KS combined with NAs improves the efficacy of NAs in CHB.





Autor: Zhe Chen, Xiao Ma, Yanling Zhao, Jiabo Wang, Yaming Zhang, Yun Zhu, Lifu Wang, Chang Chen, Shizhang Wei, Zhirui Yang, Ma

Fuente: https://www.hindawi.com/



DESCARGAR PDF




Documentos relacionados